Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid.
about
Future of bisphosphonates and denosumab for men with advanced prostate cancer.Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods.Bone mineral density changes of lumbar spine and femur in osteoporotic patient treated with bisphosphonates and beta-hydroxy-beta-methylbutyrate (HMB): Case report.
P2860
Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Risk of skeletal-related event ...... amidronate or zoledronic acid.
@en
Risk of skeletal-related event ...... amidronate or zoledronic acid.
@nl
type
label
Risk of skeletal-related event ...... amidronate or zoledronic acid.
@en
Risk of skeletal-related event ...... amidronate or zoledronic acid.
@nl
prefLabel
Risk of skeletal-related event ...... amidronate or zoledronic acid.
@en
Risk of skeletal-related event ...... amidronate or zoledronic acid.
@nl
P2093
P2860
P356
P1476
Risk of skeletal-related event ...... amidronate or zoledronic acid.
@en
P2093
James Chan
Joanne E Schottinger
Michele M Spence
Rita L Hui
P2860
P304
P356
10.1345/APH.1P152
P407
P577
2010-08-03T00:00:00Z